SRK-015 Increases Myostatin Growth Factor Levels Up to 100-fold in SMA Patients, Early Trial Data Shows
SRK-015, an investigational treatment designed to improve muscle strength and motor function in people with spinal muscular atrophy (SMA), interacts with its intended target in a dose-dependent manner, increasing by up to 100-fold the levels of latent myostatin in the blood, according to preliminary data from a Phase…